Org 27569

From WikiMD's Wellnesspedia

Org 27569 is a drug that acts as a potent and selective allosteric modulator of the cannabinoid CB1 receptor, with a novel mechanism of action. It was developed by Organon International, a pharmaceutical company based in the Netherlands.

Mechanism of Action[edit | edit source]

Unlike most CB1 antagonists, Org 27569 does not block the receptor. Instead, it changes the shape of the receptor, making it less responsive to certain types of stimulation. This is known as allosteric modulation. Org 27569 is the first drug of this kind to be discovered, and its unique mechanism of action has made it a valuable tool for researching the CB1 receptor.

Pharmacology[edit | edit source]

Org 27569 has been found to inhibit the effects of cannabinoids such as THC, the active ingredient in cannabis. However, it does not produce the same effects as other CB1 antagonists, such as Rimonabant, which can cause depression and anxiety. This suggests that Org 27569 may have potential as a treatment for cannabis dependence.

Clinical Trials[edit | edit source]

As of 2021, Org 27569 has not been tested in clinical trials. However, preclinical studies have shown promising results, and further research is ongoing.

See Also[edit | edit source]

References[edit | edit source]

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD